SST0116CL1
SST0116CL1 is a HSP90 inhibitor (IC50: 0.21 μM) . SST0116CL1 binds to the ATP binding pocket of Hsp90, and interferes with Hsp90 chaperone function thus resulting in client protein (EGFR, CDK4 and AKT) degradation. SST0116CL1 induces degradation of Her2 in BT-474 cell (IC50: 0.2 μM) . SST0116CL1 has antiproliferative activity and inhibits tumor growth. SST0116CL1 can be used for the study of leukemia, gastric and ovarian carcinoma[1].
Product Specifications
CAS Number
[1799802-29-1]
UNSPSC
12352005
Target
Akt; CDK; EGFR; HSP
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; JAK/STAT Signaling; Metabolic Enzyme/Protease; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/sst0116cl1.html
Smiles
O=C(NCC)C1=NOC(C2=CC(C(C)C)=C(O)C=C2O)=C1NC(CCN3CCOCC3)=O.Cl
Molecular Formula
C22H31ClN4O6
Molecular Weight
482.96
References & Citations
[1]Vesci L, et al. Preclinical antitumor activity of SST0116CL1: a novel heat shock protein 90 inhibitor. Int J Oncol. 2014 Oct;45 (4) :1421-9.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
7-Methyltetrazine-PO- (EO) 4-P-AParg-7-C-dATP / 7-Methyltetrazine-PEG4-AParg-7-C-dATP
